期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 16, 期 12, 页码 1397-1405出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1207530
关键词
ALS; animal models; blood-CNS barrier; clinical trials; drug therapy; patients
资金
- Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair at the University of South Florida
- National Institutes of Health [1R01 NS090962-01]
Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors.Areas covered: Numerous tested drug compounds have shown no benefits in ALS patients, although effective in animal models. Discrepant results of pre-clinical animal studies and clinical trials for ALS have primarily been attributed to limitations of ALS animal models for drug-screening studies and methodological inconsistencies in human trials. Current status of pre-clinical and clinical trials in ALS is summarized. Specific blood-CNS barrier damage in ALS patients, as a novel potential reason for the clinical failures in drug therapies, is discussed.Expert commentary: Pathological perivascular collagen IV accumulation, one unique characteristic of barrier damage in ALS patients, could be hindering transport of therapeutics to the CNS. Restoration of B-CNS-B integrity would foster delivery of therapeutics to the CNS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据